Literature DB >> 29309792

Tamoxifen inhibits fibroblast proliferation and prevents epidural fibrosis by regulating the AKT pathway in rats.

Shuguang Wang1, Xiaolei Li1, Lianqi Yan1, Qian Nie1, Jihang Dai1, Hui Chen1, Jingcheng Wang2, Yu Sun3.   

Abstract

Many factors contribute to epidural fibrosis after lumbar laminectomy, particularly the excessive proliferation of fibroblasts. Many studies have shown that tamoxifen (TAM) inhibits fibroblast proliferation and reduces fibrosis, but the detailed effect and mechanism of TAM on preventing epidural fibrosis are unknown. To investigate the effect of TAM on fibroblast proliferation and epidural fibrosis, fibroblasts were cultured and treated with different concentrations of TAM. Cell Counting Kit-8(CCK-8) detection, cell cycle analysis and western blot analysis were used to detect the roles of TAM in regulating fibroblast proliferation. Lumbar laminectomies were performed in rats, and various concentrations of TAM were administered by gavage. Histological and immunohistochemical analyses were used to evaluate the effects of TAM on preventing epidural fibrosis. CCK-8 detection showed that TAM could inhibit fibroblast viability; western blot analysis showed that TAM could decrease the expression of proliferative proteins p-AKT and cyclinD1 and increase the expression of antiproliferative proteins P21 and P27. Histological analysis showed that TAM could reduce epidural fibrosis. Immunohistochemical analysis showed that the p-ATK expression in epidural scar tissue was decreased after TAM treatment. The present study demonstrated that TAM could inhibit fibroblast proliferation and prevent epidural fibrosis, potentially through the regulation of the AKT pathway.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AKT; Epidural fibrosis; Fibroblast proliferation; Tamoxifen

Mesh:

Substances:

Year:  2018        PMID: 29309792     DOI: 10.1016/j.bbrc.2018.01.032

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Impact of sorafenib on epidural fibrosis: An immunohistochemical study.

Authors:  Osman Tanriverdi; Uzay Erdogan; Canan Tanik; Ilhan Yilmaz; Omur Gunaldi; Huseyin Utku Adilay; Ayca Arslanhan; Metehan Eseoglu
Journal:  World J Clin Cases       Date:  2018-09-06       Impact factor: 1.337

2.  Apigenin inhibits fibroblast proliferation and reduces epidural fibrosis by regulating Wnt3a/β-catenin signaling pathway.

Authors:  Rui Jiao; Hui Chen; Qi Wan; Xiaobo Zhang; Jihang Dai; Xiaolei Li; Lianqi Yan; Yu Sun
Journal:  J Orthop Surg Res       Date:  2019-08-14       Impact factor: 2.359

Review 3.  Tamoxifen Twists Again: On and Off-Targets in Macrophages and Infections.

Authors:  Chiara Sfogliarini; Giovanna Pepe; Arianna Dolce; Sara Della Torre; Maria Candida Cesta; Marcello Allegretti; Massimo Locati; Elisabetta Vegeto
Journal:  Front Pharmacol       Date:  2022-03-30       Impact factor: 5.810

4.  Tamoxifen reduces silicone implant capsule formation in a mouse model.

Authors:  Kevin M Blum; Gabriel J M Mirhaidari; Jacob C Zbinden; Christopher K Breuer; Jenny C Barker
Journal:  FASEB Bioadv       Date:  2022-08-16

5.  Antifibrotic Effect of Bletilla striata Polysaccharide-Resveratrol-Impregnated Dual-Layer Carboxymethyl Cellulose-Based Sponge for The Prevention of Epidural Fibrosis after Laminectomy.

Authors:  Hsuan-Yu Chen; Tzu-Chieh Lin; Chih-Yung Chiang; Shiuan-Li Wey; Feng-Huei Lin; Kai-Chiang Yang; Chih-Hao Chang; Ming-Hsiao Hu
Journal:  Polymers (Basel)       Date:  2021-06-29       Impact factor: 4.329

6.  Tamoxifen affects chronic pancreatitis-related fibrogenesis in an experimental mouse model: an effect beyond Cre recombination.

Authors:  Xuan Li; Christian Clappier; Ingo Kleiter; Rainer Heuchel
Journal:  FEBS Open Bio       Date:  2019-09-07       Impact factor: 2.693

7.  Laminin α5 modulates fibroblast proliferation in epidural fibrosis through the PI3K/AKT/mTOR signaling pathway.

Authors:  Pengran Liu; Hui Chen; Lianqi Yan; Yu Sun
Journal:  Mol Med Rep       Date:  2020-01-28       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.